Clinical Trial Update: A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention [Phase 2]

View source ↗

Summary

This Phase 2 randomized, double-blind, placebo-controlled trial of BGG492 for migraine prevention has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• BGG492

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Patients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening | Phase 2 | Status: WITHDRAWN